Author, date, study type, level of evidence, Heyland score | Patient group | Complications reported | Nutritional outcomes |
Dann et al. 2015
Retrospective Cohort Study
CEBM Level 4
Heyland Score (/11) | Total = 345
J-tube = 186 (53.9%)
No J-tube = 159 (46.1%) | Any Complication: 57.5% JT vs. 45.9% No JT*
Major Complication^: 26.3% JT vs. 23.3% No JT
Infectious Complication: 38.7% JT vs. 25.8% No JT*
Surgical Site Infection: 15.1% JT vs. 8.2% No JT
Deep Intra-Abdominal Infection: 12.9% JT vs. 5.7% No JT*
Reoperation: 13.4% JT vs. 8.8% No JT
30-Day Readmission: 15.6% JT vs. 17.0% No JT | Length of Stay (days): 14.4 (±9.9) JT vs. 11.4 (±8.8)*
Adjuvant Chemotherapy: 55.9% JT vs. 56.8% No JT
Adjuvant Radiation Therapy: 37.7% JT vs. 33.8% No JT
Any Adjuvant Therapy: 56.5% JT vs. 56.8% No JT |
Heylen et al. 1987
Prospective Randomised Control Trial
CEBM Level 2
Heyland Score (/11): 5 | Total = 20
J-tube = 10 (50%) TPN = 10 (50%) | JT: Catheter Complications: 0% Superficial Wound Abscess: 10%
No Other Complications Reported
TPN: Thrombosis: 10% Superficial Wound Abscess: 10% Deep Abscess: 10%
No Other Complications Reported | Actual Calorie Intake vs. Prescribed Amount: JT: 83% of Intended Target TPN: Identical to Prescribed Amount
Total Caloric Intake**: JT: 11,690 kcal/pt/8 days vs. TPN: 12,200 kcal/pt/8 days
Weight Loss: JT: 3.7 kg vs. TPN: 5.1 kg*
Mid-Upper Arm Circumference JT: −1.6 cm vs. TPN: −0.4 cm
Blood Biochemistry at Day 8***: No Significant Difference between JT and TPN |
Patel et al. 2013
Retrospective Cohort Study
CEBM Level 4
Heyland Score (/11): 5 | Total = 46
J-tube: 32 (69.6%)
No J-tube: 14 (30.4%) | Any Complication: 53% JT vs. 43% No JT
Infectious Complication: 34% JT vs. 14% No JT
Major Complication^: 6% JT vs. 0% No JT
Reoperation: 3% JT vs. 0% No JT
Bleeding Requiring Packed RBC Transfusion: 0% JT and No JT
Anastomotic Leak: 0% JT and 0% No JT
30-Day Readmission: 22% JT vs. 21% No JT | Length of Stay (days): 14 (8 - 30)a JT vs. 10 (5 - 15)a No JT*
Albumin Pre-Operative: 3.4 (1.8 - 4.2)a JT vs. 3.2 (2.1 - 4.1)a No JT
Albumin 30-Day: 2.9 (1.12 - 3.8)a JT vs. 2.7 (2.0 - 3.3)a No JT
Albumin 60-Day: 3.2 (1.3 - 4.4)a JT vs. 2.7 (2.0 - 3.7)a No JT
Albumin 90-Day: 3.5 (1.9 - 4.5)a JT vs. 3.2 (2.7 - 3.6)a No JT
Received Adjuvant Therapy Post-Op: 66% JT vs. 57% No JT |